Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Rational Dosage Regimen: Maintenance Dose and Loading Dose

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Dosage Regimen: Individualization

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

Dosage Regimen: Fixed Dose

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Transcriptomic profiling of the middle temporal gyrus reveals differential glial/neuronal dysregulation across Alzheimer's disease and aging.

bioRxiv : the preprint server for biology·2025

Same author

Severe Maternal Morbidity and the Impact of the Covid Pandemic.

Irish medical journal·2023

Same author

Severe maternal morbidity trends over 20 years in a tertiary referral stand-alone maternity unit.

European journal of obstetrics, gynecology, and reproductive biology·2023

Same author

Systemic artery to pulmonary artery aneurysm malformations associated with variants at MCF2L.

American journal of medical genetics. Part A·2023

Same author

Herbivore-Dependent Induced Volatiles in Pear Plants Cause Differential Attractive Response by Lacewing Larvae.

Journal of chemical ecology·2023

Same author

Maternal and Neonatal Outcomes During the First Year of the Covid-19 Pandemic.

Irish medical journal·2022

Search research articles

Related Experiment Videos

Hydroxocobalamin dose escalation improves metabolic control in cblC.

N Carrillo-Carrasco¹, J Sloan¹, D Valle²

¹Organic Acid Research Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Building 49, Room 4A18, Bethesda, MD, 20892, USA.

Journal of Inherited Metabolic Disease

|October 13, 2009

Summary

Cobalamin C (cblC) is a metabolic disorder treated with hydroxocobalamin (OHCbl). Higher OHCbl doses improved metabolic markers in a patient with cblC, suggesting potential benefits for treatment optimization.

Related Experiment Videos

Area of Science:

Biochemistry
Genetics
Metabolic Disorders

Background:

Cobalamin C (cblC) deficiency is the most common inherited disorder of intracellular cobalamin metabolism.
Newborn screening can detect cblC, which presents acutely and can be fatal if untreated.
Intramuscular hydroxocobalamin (OHCbl) is the standard treatment, but lacks formal dosing guidelines.

Observation:

A 13-year-old boy with cblC experienced worsening metabolic parameters despite standard treatment.
The patient's OHCbl dosage was increased from 1 mg to 20 mg IM daily.
A dose-dependent biochemical response was observed with increasing OHCbl dosage.

Findings:

Plasma methylmalonic acid (MMA) decreased by 80% (25 to 5.14 µmol/L).
Total homocysteine (tHcy) levels reduced by 55% (112 to 50 µmol/L).
Methionine levels more than doubled (17 to 36 µmol/L).

Implications:

Higher intramuscular OHCbl doses may be necessary for optimal biochemical control in cblC patients.
Further clinical trials are needed to evaluate the efficacy of high-dose OHCbl therapy.
The long-term impact of increased OHCbl dosing on cblC complications requires investigation.